TransMedics Group (TMDX)
(Delayed Data from NSDQ)
$139.00 USD
-1.49 (-1.06%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $139.05 +0.05 (0.04%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth B Momentum D VGM
TransMedics (TMDX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$146.38 | $175.00 | $117.00 | 4.19% |
Price Target
Based on short-term price targets offered by eight analysts, the average price target for TransMedics comes to $146.38. The forecasts range from a low of $117.00 to a high of $175.00. The average price target represents an increase of 4.19% from the last closing price of $140.49.
Analyst Price Targets (8 )
Broker Rating
TransMedics currently has an average brokerage recommendation (ABR) of 1.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 1.33 a month ago based on nine recommendations.
Of the nine recommendations deriving the current ABR, seven are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 77.78% and 11.11% of all recommendations. A month ago, Strong Buy made up 77.78%, while Buy represented 11.11%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 6 | 6 |
Buy | 1 | 1 | 1 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.33 | 1.33 | 1.33 | 1.29 | 1.29 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/6/2024 | C.L. King & Associates | Kristen M Stewart | Moderate Buy | Moderate Buy |
6/4/2024 | Stephens | George Sellers | Not Available | Strong Buy |
5/1/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/1/2024 | Piper Sandler | Matthew O'Brien | Strong Buy | Strong Buy |
5/1/2024 | Canaccord Genuity | Jason R Mills | Strong Buy | Strong Buy |
4/30/2024 | William Blair | Ryan S Daniels | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Joshua T Jennings | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.33 |
ABR (Last week) | 1.33 |
# of Recs in ABR | 9 |
Average Target Price | $146.38 |
LT Growth Rate | NA |
Industry | Medical - Instruments |
Industry Rank by ABR | 100 of 252 |
Current Quarter EPS Est: | 0.21 |